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An important aspect of clinical laboratory quality 
management is ‘Quality Assessment’, and it can 
be conducted in several ways. Internal quality 
control compares laboratory performance to 
itself over time, assuming that the performance 
observed earlier represents correct or accurate 
test results. This assumption should be validated 
initially by method validation experiments and 
must be validated on a continuing basis by 
external quality assessment (EQA) or profi ciency 
testing (PT) programs. It is also mandated by 
accreditation bodies that laboratories participate in 
PT programs for all types of analyses undertaken 
in that laboratory. In cases where PT programs are 
not available for a specifi c analytes alternate PT 
methods (split sample testing, sending specimen to 
reference laboratory for analysis) should be adopted 
for EQA. 
An Overview of Profi ciency Testing 
From the Editor’s Desk
Dr Hafsa Majid
Chemical Pathology
In the last decade, there has been a rapid expansion 
of healthcare services in Pakistan. Correspondingly, 
the consumer knowledge has also increased and they 
demand quality services in timely manner. Clinical 
laboratory is the center point of these services as over 
70 per cent decisions are taken based on laboratory 
results.
The most important component throughout this 
whole process is quality assurance. With increasing 
awareness amongst patients along with increasing 
costs, a signifi cant onus and urgency is placed on 
clinical laboratories to ensure that quality and error 
free work practices are maintained.
Over the years, the improvement in the quality of 
tests and methodology has been steady. Following 
the introduction of laboratory automation, quality 
assurance has been taken to a new level. Instruments 
have been interfaced with various laboratory 
automated systems and subsequently, information 
technology has drastically reduced human 
intervention during analytical procedure without 
compromising on the level of care.
Errors and challenges continue to occur but time has 
indicated that the path to improvement is not always 
a straight line; there are periods of success and 
periods of massive failures. Laboratory improvement 
has been a steadfast experience till now. One lesson 
to be learnt from this experience is that we cannot 
predict all errors; but through active quality process 
we can detect errors earlier and prevent them from 
happening. 
This issue has been focused on articles pertaining to 
quality assurance in a clinical laboratory. The articles 
have been carefully selected so that our readers 
can build upon the culture of quality assurance and 
increase knowledge of the same by following the 
goal of continuous improvement.     
Dr Natasha Ali
Haematology 
The EQA or PT programs refer to the process of 
controlling the accuracy of an analytical method 
by interlaboratory comparisons. This comparison 
can be made to the performance of a peer 
group of laboratories or to the performance of a 
reference laboratory. The key requirements of such 
comparisons are that the samples are homogenous 
and stable, matrix is as similar as possible to patient 
specimen and the instrument, method, calculations 
and units used are appropriate and similar to 
comparing laboratories. 
Benefi ts of PT Programmes
Profi ciency testing is used to judge the quality of 
laboratory testing.The unique capability of an EQA 
program is to monitor the accuracy of methods/
instruments and make sure that the performance 
4VOL. 41, ISSUE 1MARCH 2015
of a laboratory’s method is stable on the period 
between two surveys. Harmonization of results 
among laboratories and among methods is another 
important objective of EQA because clinical practice 
guidelines can be standardized if results are consistent 
among different laboratories. By participating in 
PT programs, a laboratory can maintain a level of 
competence comparable with other laboratories. 
Continued and signifi cant deviation in PT should alert 
a clinical laboratory to a possible accuracy problem. 
PT Providers
Multiple private organizations are providing PT surveys 
of different analytes. Common ones include College of 
American Pathologist, American Profi ciency Institute, 
United Kingdom National External Quality Assessment 
Service, Centers for Disease Control and Prevention, 
BIO-Rad External Quality Assessment Services and 
National External Quality Assurance Program Pakistan. 
Two types of surveys are available; peer group 
comparison and accuracy based survey. In accuracy 
based survey actual value of PT sample measured 
by a reference method and individual laboratory’s 
results are compared with true or target value of PT 
specimen. Profi ciency testing provider is selected on 
basis of national and regulatory agencies requirement, 
previous surveys of that PT provider, surveys taken 
by other regional laboratories, cost of surveys, type 
of comparison and commutability of PT specimen. 
Frequency of PT testing is recommended by different 
regulatory authorities, at least twice a year and more 
frequent for routine analytes. 
PT Report Interpretation
Peer group comparison is the common method used 
by PT providers, same PT specimen is sent to all 
laboratories participating in a survey and results 
are reported as mean, standard deviation (SD), 
standard deviation index (SDI), control limits for 
each analytes and graph of previous and current 
survey. A peer group is comprised of at least 10 or 
more laboratories performing same analyte on same 
instrument using same method and reporting in 
similar units. If no peer group is formed laboratory 
is evaluated against all methods mean. Limits for 
all analytes is different based regulatory authority’s 
acceptability criteria and biological variation. A 
laboratory’s results are acceptable if within limits. 
Standard deviation index (SDI) is another accuracy 
measure calculated by (Laboratory’s mean – Peer 
group mean)/ Peer group SD and it should be 
<2. Acceptable PT results with high SDI should 
alert laboratory to system’s bias. Last to look at 
in a PT survey is graph for bias. Ideally a graph 
should show PT results near and on both sides 
of mean. Graph showing results of previous and 
current surveys on one side of mean shows positive 
or negative bias in a system. For a survey to be 
acceptable at least 80% of PT results should be 
acceptable. 
Profi ciency testing results can be affected by 
preparation/ transport conditions of the PT 
specimens, matrix effects, clerical errors, selection 
of statistical methods of evaluation, and peer group 
defi nition. It is not appropriate to use PT as the only 
means for evaluating the quality of a laboratory 
as it will not detect all problems in the laboratory, 
particularly those that address the pre and post 
analytical processes. In conclusion PT programs 
can be an effi cient tool in assessing a laboratory’s 
analytical systems/methods. However complete 
utility of any PT program requires complete 
understanding of the PT report issued.
Laboratory testing can be divided into three phases 
that is pre-analytical phase which begins with 
the patient and ends with preparation of a sample 
for testing, analytical phase which includes steps 
involved in the actual performance of a laboratory 
test and post analytical phase which begins with the 
reporting of results to the health care provider and 
ends with actions being taken by the health care 
provider that are based on test results. A common 
assumption is that errors are most likely to occur in 
the analytical phase, the component of laboratory 
testing considered the most complex. Perhaps 
Sources of Pre-analytical Variations
Dr Khushbakht Arbab
Chemical Pathology
5VOL. 41, ISSUE 1MARCH 2015
as a consequence of the focus on technological 
improvements, it is actually the pre-analytical phase 
in which most errors occur. The healthcare providers, 
laboratory staff and the patients themselves should 
be aware of the common causes of pre-analytical 
errors. These errors can be further divided into 
pre-collection, blood collection and post collection 
causes (Table 1). To prevent pre-analytical errors, the 
procedures for collection, handling, and processing 
prior to analysis, as well as the physiologic patient 
variables that may directly affect the test result, must 
be clearly understood.
Specimen composition is infl uenced by any of 
the patient variables listed in Table 1. Some 
are controllable, some are not. The laboratory 
personnel must be aware of these infl uences and 
minimize the effects when possible. For example, 
in the basal state, a patient is at rest and fasting. 
Collection of a blood specimen from a patient in 
that state minimizes the effect of diet, exercise, 
and other controllable factors. A broad category 
of variables related to phlebotomy technique and 
procedures can introduce pre-analytic error. A 
few studies have demonstrated that pre-analytical 
errors are less common when dedicated laboratory 
personnel collect blood samples as opposed to 
nursing or other health care personnel. Unacceptable 
specimens due to misidentifi cation, insuffi cient 
volume to perform the assay, incorrect whole 
blood to anticoagulant ratio, or specimen quality 
issues (specimens that are hemolyzed, clotted, 
contaminated, or collected in the wrong container) 
account for the majority of pre-analytic errors. 
Hemolysis, lipemia, and icterus have variable effects 
on assays. How a specimen is handled from patient 
to laboratory is another area of potential error and 
mostly outside control of the testing laboratory. 
Careful handling of the specimen during transport 
and processing is imperative in maintaining the 
quality of a meticulously collected specimen. The 
means of transport, exposure to heat and cold, 
vibration, position of specimen tubes and overall 
time to delivery can signifi cantly affect test results. 
The pre-analytical phase is complex and with 
so many people involved in the blood collection 
process, it is not surprising that errors can 
occur. However, good practices, teamwork, and 
compliance with the established procedures and 
instructions can lead to a substantial reduction in 
pre-analytical errors.
Table 1: Preanalytical Causes of Errors Divided into Pre-collection, Blood collection and Post collection Phases
Blood Collection Phase Variables
Posture
Time of collection
Faulty phlebotomy technique
Tourniquet time (not >1 minute)
Skin preparation
Hemolysis 
Clots in sample
Under fi lling of tubes
Cross contamination between tubes
Skin contamination
Inadequate mixing
Quantity not suffi cient for analysis
Wrong vacutainer tube 
Wrong order of draw
Air introduced in the sample
Venous sampling when arterial blood  
 is required or venous mixing
Presence of intravenous fl uids on the  
 arm
Pre-collection Phase Variables
 Wrong/ inappropriate test request
Test request written illegible
Patient contributions:
 Diurnal consideration
 Fasting requirement for certain tests
 Exercise
 Stress
 Age
 Medications
 Smoking
 Dehydration
Wrong labeling/ wrong barcode
Post Collection Phase Variables
Exposure to sunlight
Exposure to inappropriate temperature
Delay in transport
Hemolysis 
Breakage or leakage
Delay in processing
Evaporation
Faulty centrifugation
Poor specimen storage condition
Incorrect aliquots
Wrong labeling
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Critical Values in Surgical Pathology
Dr Nausheen Azam and Dr Arsalan Ahmed
Histopathology
Occasional diagnoses in surgical pathology, 
analogous to critical values (CVs) in clinical 
pathology, could require urgent contact of the 
clinician to facilitate rapid intervention.  However, 
there are no established guidelines as to what type 
of diagnosis in surgical pathology should qualify as 
a critical value (CV).
The concept of critical value (CV) was 
fi rst introduced by Lundberg in 1972 as a 
“pathophysiologic derangement at such variance 
with normal as to be life threatening if therapy 
is not instituted immediately.”  Since the 
introduction of the CV concept, the practice 
of notifying clinicians of CVs has become the 
standard of practice in clinical pathology, with 
well established guidelines for which specifi c 
laboratory results require that the laboratory 
personnel immediately contact the clinician 
responsible for the patient.  The Clinical 
Laboratory Improvement Amendments of 1988, 
states that “the laboratory must develop and follow 
written procedures for reporting life threatening 
laboratory results or panic values.”  The College 
of American Pathologists (CAP) checklist also 
includes a requirement asking if there is a policy/
procedure regarding the timely communication and 
documentation of “signifi cant” or “unexpected” 
surgical pathology fi ndings.
However there are no well defined guidelines 
to address the concept of CVs in surgical 
pathology.  Therefore in the absence of 
established guidelines and since surgical 
pathology results are not measured in numbers, 
common sense and personal experience of the 
pathologist determines when to urgently contact 
the clinician.
Cases that have immediate clinical consequences 
Crescents in > 50% of glomeruli in a kidney biopsy
Leukocytoclastic vasculitis 
Uterine contents without villi or trophoblast
Fat in an endometrial curettage
Mesothelial cells in a heart biopsy
Fat in colonic endoscopic ploypectomies
Transplant rejection
Maligancy in superior vena cava syndrome
Neoplasms causing paralysis
Unexpected or discrepant fi ndings
Signifi cant disagreement between frozen section and fi nal diagnosis
Signifi cant disagreement between immediate intepretation and fi nal FNA diagnosis 
Unexpected malignancy
Signifi cant disagreement and/or change between primary pathologist and outside pathologist consultation (at 
either the orginal or consulting institution)
Infections
Bacteria or fungi in cerebrospinal fl uid cytology in immunocompromised or immunocompetent patients
Pneumocystis, fungi, or viral cytopathic changes in bronchoalveolar lavage,bronchial washing or brushing 
cytology specimens in immuncompromised or immunocompetent patients
Fungi in FNA of immuncompromised patients
Bacteria  in heart valve or bone marrow
Herpes in Papanicolaou tests of near-term pregant patients
Any invasive organism in surgical pathology specimens of immuncompromised patients 
Table 1: Examples of Critical Diagnoss in Anatomic Pathology
Abbreviation: FNA, Fine needle aspiration
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The Association of Directors of Anatomic and 
Surgical Pathology (ADASP) has supported the 
concept of critical diagnoses (CVs) in surgical 
pathology, recognizing that critical diagnosis 
guidelines would be of great help to surgical 
pathologists and, ultimately, facilitate the clinicians. 
As a result, several retrospective reviews and multi-
institutional surveys led to the creation of a list of 
possible critical diagnoses in surgical pathology and 
cytology (Table 1).
ADASP recognizes that a generic anatomic 
pathology critical diagnosis guideline such as the one 
mentioned above should be used only as a template 
and it should be left to the individual hospital to 
customize the list following consultation with their 
relevant clinical services. While establishing the CVs 
guidelines it is also important to avoid overuse and 
remove non-critical diagnosis type cases from the 
list.
In conclusion, it is important to establish a 
surgical pathology CV guideline, because there 
are some diagnoses in surgical pathology which 
are life threatening and require fast remedial 
action for improved patient outcome, and 
secondly the presence of these guidelines would 
represent a practice improvement and patient 
safety initiative. 
References:
Lundberg GD. When to panic over an abnormal value.  MLO Med Lab 
Obs 1972;4:47-54
Critical diagnoses (critical values) in anatomic pathology. Human 
Pathology (2006)37, 982-984
Five Q-Framework for Implementing Total 
Quality Management in Laboratory
There has been a continuous challenge in the health 
care system to provide better diagnosis, while 
maintaining standard quality credentials. Total 
Quality Management (TQM) include all divisions 
of the organization, namely, laboratory operations, 
information management, documents and record 
maintenance, materials and purchase, customer 
care, safety etc.  Quality Management System 
requirements cover management’s commitment to 
quality, its focus on customer, resource management, 
employee competence, process management, 
quality planning, design, purchasing, monitoring 
and measurement of its processes, calibration of 
measuring equipment, processes to resolve customer 
complaints, corrective/preventive actions and 
continuous quality improvement program. 
The traditional framework for quality management in 
a healthcare laboratory emphasizes the establishment 
of following processes i.e. (Figure 1) 
(1) Quality Laboratory Processes (QLPs) 
(2) Quality Control (QC) 
(3) Quality Assessment (QA)
(4) Quality Planning (QP) and
(5) Quality Improvement (QI)
QLPs include analytical processes and the general 
policies, practices, and procedures that defi ne how 
all aspects of the work are done. QC emphasizes 
statistical control procedures, but also includes 
non-statistical check procedures, such as linearity 
checks, reagent and standard checks, and temperature 
Dr Noreen Sherazi
Chemical Pathology
Figure 1: TQM Framework for Managing Quality in Healthcare Laboratory
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monitors.  QA, as currently applied, is concerned 
primarily with broader measures and monitors of 
laboratory performance, such as turnaround time, 
specimen identifi cation,  patient identifi cation and  
test utility. Note that QA is the proper term for these 
activities, as opposed to quality assurance, which 
has been incorrectly used to describe these activities. 
Measuring performance does not by itself improve 
performance and often does not detect problems in 
time to prevent harmful effects. QA requires either 
that causes of problems be identifi ed through Ql and 
eliminated through quality planning (QP) or that QC 
detect the problems early enough to prevent their 
consequences.
To provide a fully developed framework for quality 
management, the QI and QP components must 
be established. QI provides a structured problem-
solving process to help identify the root cause 
of a problem and a remedy for that problem. QP 
is necessary to standardize the remedy, establish 
measures for performance monitoring, ensure that the 
performance achieved satisfi es quality requirements 
and document the new QLP. The new process then is 
implemented through QLP, measured and monitored 
through QC and QA, improved through QI, and 
replanned through QP. The “fi ve-Q framework” also 
defi nes how quality is managed objectively with 
the “scientifi c method,’’ or the PDCA cycle (plan, 
do, check, act). QP provides the planning step, QLP 
establishes standard processes for the way things 
are done, QC and QA provide measures for checks 
on how well things are done, and QI provides a 
mechanism through which, to act on those measures.
Clinical and Laboratory Standards Institute (CLSI) 
document  describes a quality management system 
(QMS) as a “set of key quality elements that must 
be in place for an organization’s work operations 
to function in a manner to meet the organization’s 
stated quality objectives.” These Quality System 
Essentials (QMEs) are listed in Table 1. These depict 
the necessary infrastructure required by a laboratory 
to provide quality laboratory services which is 
implemented and monitored by fi ve Q-framework to 
achieve the quality goals.
Table 1: Essentials of TQM
Organization
Customer Focus
Facilities and Safety
Personnel
Purchasing and Inventory
Equipment
Process Management
Documents and Records
Information Management
Nonconforming Event Management 
Assessments
Continual Improvement
Reference: CLSI guidelines QMS: A Model for Laboratory Services 
GP26-A4
Delta Check in Clinical Laboratory
Decisions about diagnosis, prognosis and treatment 
are based on the results and interpretations of 
laboratory tests, and irreversible harm may be caused 
by erroneous test results. So early error identifi cation 
have considerable implications for patient care 
and safety. Delta check is a very useful quality 
improvement measures that can help the laboratory 
identify possible patient-specifi c errors. It is a quality 
control method that compares the current test result 
with a previous result for the same test obtained over 
a short period of time (preferably within 96 hours) 
from the same patient and detects whether two values 
exceeds predetermined biological limits. A delta 
check failure or alert is caused by a discrepancy in 
patient results. It occurs when the difference between 
the patient’s current laboratory result and previous 
result exceeds a pre-defi ned limit with a pre-defi ned 
length of time.
Delta check methods ensure the detection of pre-
analytical errors (e.g. specimen mix-up errors, 
improper specimen acquisition, specimens altered by 
dilution with intravenous fl uid, EDTA contamination, 
possible misidentifi cation of a specimen and 
Hafsa Majid
Chemical Pathology
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transport error), clerical errors, biological variation 
(e.g. changes due to due to rhythmic, physiological 
or therapeutic changes) and random errors (e.g. 
sudden instrument or method related errors). If no 
error is identifi ed in total testing process differences 
in results is due to a true change in patient’s disease 
status. These errors cannot be detected using 
commonly used quality control methods; thereby 
delta check improves the reliability of clinical tests.
There are four delta check methods: delta difference, 
delta percent change, rate difference, and rate percent 
change. However, guidelines regarding decision 
criteria for selecting delta check methods have not 
yet been provided. Delta check methods statistically 
can be defi ned as:
 Delta Difference = Current Result – Previous Result
 Delta Percentage Change = Current- Previous Result X 100%
           Previous Result
 Rate Difference = Delta Difference / Delta Time
 Rate Percentage Change= Delta Percentage Change/Delta Time
Studies have found that the majority of delta check 
failures (>75 per cent) can be attributed to true 
changes in the patient’s medical condition and 
predictive value for detecting true specimen errors 
is between 0.4 and six per cent. Some analytes are 
more useful for delta checks than others. Ideally, 
analytes for delta checks should have little day-to-
day variation, low reference change value and low 
index of individuality. Some common analytes on 
which delta check can be applied are listed in Table 1.
Table 1: Biochemical Analytes for Delta check Application
Appropriate analytes Inappropriate analytes
Electrolyte ( Na+, K+ & Cl-) Glucose
Albumin Phosphorus
Total Protein Aspartate transaminase
Urea Alanine transaminase
Creatinine Creatinine Phosphokinase
Alkaline Phosphatase Lactate Dehydrogenase
Modern automated analyzers now have the option 
of delta check fl ags in them. However to make this 
function practically possible delta check limits have 
to be derived for each analyte. In conclusion the 
delta check based quality control is very useful in 
identifying errors missed by laboratory quality control 
procedures and these programs should be performed 
in parallel with routine quality control practices.
Indicators of Quality Improvement in 
Surgical Pathology
A quality assurance program is meant to identify 
problems and recognize opportunities for 
improvement. The fi rst step is the development of 
quality indicators which cover the most important 
aspects of patient care. Only few quality indicators 
have been identifi ed by the surgical pathology 
laboratories worldwide.  Few important variables of 
analytic and postanalytic phase are described in this 
article.
Diagnostic Accuracy (Intradepartmental Peer 
Review)
Quality in surgical pathology depends on the 
correctness of report which is assured by peer 
review which provides the opportunity to collect 
comprehensive information and straightforward 
identifi cation of quality issues. Retrospective 
peer review often targets diagnostic biopsies 
with increased potential for adverse outcomes, 
recent cancer diagnoses, specifi c specimen types 
with known diagnostic diffi culties and frequent 
mimics. The common examples include daily slide 
conference and reviews requested by the clinician 
in case of report ambiguity and lack of correlation 
with clinical fi ndings. Other activities such as tumor 
boards, audits of cases sent to outside institution 
for routine review and audits focused on specifi c 
specimen types.
The responsibility remains with the primary sign-
out pathologist who issues a revised/amended 
report if the diagnosis is after the review is 
changed.
Dr Muhammad Usman Tariq and Dr Arsalan Ahmed
Histopathology
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Diagnostic Accuracy 
(Interinstitutional Peer Review):
 
External review can be initiated 
on the request of patient, 
clinician or pathologist but most 
importantly on institutional 
request because of patient’s 
transfer. Studies have shown 
that these reviews revealed 
discordance in diagnosis including 
false –positive, false-negative, 
change in tumor type/grade, 
resection margin status and stage 
change. In addition, application 
of additional and/or repeat 
immunohistochemical stains 
results in significant change in 
diagnosis. In future, molecular 
diagnostics is further going to 
alter the diagnosis when reviewed 
in different institutions. For institutions treating 
new patients, the Association of Directors of 
Anatomic and Surgical Pathology (ADASP) 
recommends mandatory review of biopsy of 
cases for which major therapeutic intervention is 
planned.
Correlation of Intraoperative and Final Diagnosis 
(Frozen Sections)
It is an integral component of quality 
improvement and it should be conducted on all 
the cases submitted for frozen section. It requires 
review of the slides prepared for frozen section 
and the slides prepared after formalin fixation. 
Reasons for discordant results (in order of 
decreasing frequency) include misinterpretation, 
specimen sampling, block sampling, 
technical inadequacy, inadequate clinical 
data and labeling errors.
Report Adequacy
Adequacy or completeness of the report 
is extremely important in cancer cases 
as the treatment relies on the complete 
information. College of American 
Pathologists and Royal College of 
Pathologists have devised comprehensive 
checklists and protocols for different 
cancers. Laboratories all over the world 
are adopting the synoptic reporting which 
presents all the essential information (data 
elements) required in an efficient manner. 
Moreover, monitoring of the reports for missing 
information has now become easier.
Turnaround Time (TAT)
TAT is as important as diagnostic accuracy and 
adequacy of a report and therefore, it is a critical 
component of patient care because of its impact 
on patient management. It is infl uenced by several 
factors related to the working of a hospital, 
anatomic pathology laboratory, with technical, 
clerical and human interpretive processes. 
Turnaround time data can help to identify the 
problems, their analysis and possible modifi cation 
of the process in order to improve the overall 
service and eventually patient outcome. 
Table 1: Monitors used to Assess Report Adequacy
Reference: Quality Management in Anatomic Pathology. Chapter 6: Quality improvement 
plan components and monitors. 2005 College of American Pathologists (CAP)
Table 2. ADASP Benchmarks for Surgical Pathology Turnaround Times
 Data Element
Specimen of any type Patient identifi cation
 Pertinent clinical history
 Specimen site
 Statement of specimen adequacy (when appropriate) 
 Adequate macroscopic description
 Clear diagnostic terminology
Primary cancer specimens Tumor size
 Histologic type
 Histologic grade (if appropriate)
 Extent or depth of invasion (if appropriate)
 Number of lymph nodes examined 
 Number of nodes with metastasis (if any)
 Status of surgical margins (if appropriate)
Image-guided biopsies A comment on specimen adequacy
 A comment on whether the biopsy fi ndings correlate  
 with the imaging fi ndings (eg. whether the fi ndings  
 explain the targeted abnormality)
 The presence of calcifi cation in a biopsy performed  
 for that reason
Type of Specimen Report Finalization
Frozen sections 20 minutes 
Rush biopsies 2 days
Biopsies (small) 3 days
Surgical specimens 3 days 
Additional Time for Special Procedures
Overnight fi xation 1 day
Decalcifi cation 1 day
Regrosses 1-2 days
Recuts 1 day
Immunohistochemistry 1-2 days 
Electron microscopy 2-3 days
Intradepartmental consultation 1 day
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Figure 1: Representation of the values’ dispersion in RE
Figure 2: Representation of the values’ dispersion in SE
Types of Analytical Errors
Shabnam Dildar
Chemical Pathology
Laboratory errors are normally classifi ed into two 
categories; random errors (RE) and systematic 
errors (SE). Random errors are type of analytical 
error which arises from random fl uctuations in 
measurement (Figure 1). Systematic error is defi ned 
as a component of error which, in the course of a 
number of analyses of the same analyte, remains 
constant or varies in a predictable way (Figure 2). 
Total analytical error =SE + RE. Statistically total 
error is defi ned as Bias + 1.65 x Imprecision. Under 
ideal circumstances, total analytical error equals to 
zero, but this cannot be achieved in daily practice. 
Random Errors: cannot be absolutely identifi ed 
(can occur due to differences in 
techniques between technologists, 
specimen characteristics, etc.) Some 
common causes of RE are:
 Instability of instrument
 Variation in the temperature
 Variation in reagents and calibrators  
 (poor calibration curve stability)
 Variation in handling techniques such    
 as pipetting, mixing, and timing
 Variability in operators
Random error affect the precision of all measurements, 
higher the precision of a measurement instrument, 
the smaller the variability (standard deviation) of the 
fl uctuations in its readings. Large RE increases the 
dispersion of the results around a true value. 
Systematic Error: Systematic errors can be 
attributed to certain reasons and therefore can 
be eliminated much easier than RE. They cannot 
be diminished by increasing the number of 
measurements. Some common causes of SE are:
 Incorrectly made standards, controls or reagents
 Instrumentation defects
 Variation in pipettes and volumetric glassware
 Variation in cuvettes
 Electronic and optical variation in instruments
Systematic errors are subdivided into the following 
two types:
Constant systematic error: When the error is 
consistently low or high by the same amount, 
regardless of concentration it is called constant 
systematic error. Factors that contribute to constant 
systematic error are independent of analyte 
concentration.
Proportional systematic error: When the error is 
consistently low or high by an amount proportional 
to the concentration of analyte is called proportional 
systematic error.
Table 1 presents an organization of experiments to be 
performed for specifi c error determination arranged 
in such a way that easy experiments can be done fi rst 
and fi nal performed only if errors estimated by these 
preliminary experiments are acceptable.
Table 1: Experiments for Estimating Specifi c Types of Analytical Errors.
Preliminary Study
Replication With In Run (using 
pure material, patient specimens)
Interference
Recovery
Final Study
Replication run to run 
(using patient specimens)
Comparison with       
comparative method
Comparison with      
comparative method
Evaluation ExperimentsType of Analytic 
Error
RE
Constant Error
Proportional Error
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Flow cytometry is a dynamic technology 
which allows the multi-parameter evaluation of 
heterogeneous cell populations. Over the years, 
clinical fl ow cytometry has evolved as a distinct 
haematopathology diagnostic facility. Considering 
the requirement put forth by regulatory agencies 
and the complexity of multi-parameter analysis by 
fl ow cytometry, standardization and validation of 
fl ow cytometry instrument, reagents and procedures 
are essential to ensure interpretation of meaningful 
technical results. In this article, validation of fl ow 
cytometry instrument will be the primary focus.
Validation of fl ow cytometry instrument includes 
instrument setup, daily calibration of both light 
scatter and fl uorescence measurements and cross-
instrument performance using relevant clinical 
specimens.
Instrument Setup
Manufacturer recommended procedures must 
strictly be followed to assure proper optical 
alignment for adequate light scattering, 
fl uorescence sensitivity and resolution. Additionally 
when multiple fl uorochromes are used, fl uorescence 
compensation is essential to correct for spectral 
overlap. 
Calibration of Light Scatter and Fluorescence 
Measurements
Optical alignment for optimal sensitivity and 
resolution of both forward (FSc) and side (SSc) 
scatter can be assessed by running uniformly 
sized beads that fall within the light scatter ranges 
observed with most clinical samples on a daily 
basis. The mean FSc and SSc channel numbers 
and percent coeffi cient of variation (CV) should 
be recorded. The acceptable ranges for each 
parameter can be established by running the beads 
20 times over a fi ve day period at the same photo 
multiplier tubes (PMT) setting. Levy–Jennings 
graphs are then used for validation by plotting 
the values obtained daily and an action plan is 
established for what to do when any parameter 
falls outside of the expected range. Owing to the 
difference in behavior of cells and beads, setting 
up of instrument using biological material (for 
example lymphocytes) is also recommended 
before running clinical samples. Similarly for 
establishing values for monitoring fl uorescence 
sensitivity and resolution, recording of either the 
channel number and C.V of calibration beads or 
alternatively, the high voltage and gain to position 
the beads in the same channel each time.
Utilization of multiple fl uorochromes is associated 
with spill-over of one fl uorescence signal into 
another. For this, fl uorescence compensation using 
a combination of biological control and hard dyed 
beads provided by manufacturer is preferable. For 
fl uorescence linearity, a mixture of 4-5 known multi-
level fl uorescence beads should be run 20 times over 
a fi ve days period to establish mean fl uorescence 
intensity (MFI) ranges. Monthly fl uorescence 
linearity should be stable unless the laser or PMT is 
unstable.
Cross-Instrument Performance 
It should be done by laboratories performing the 
same clinical immunophenotyping protocols on more 
than one instrument. Five different representative 
clinical samples must be tested every six months. 
Corrective actions must be taken when cross-
comparison results fail to meet performance 
specifi cations.
 
In conclusion, validation of instruments, reagents 
and procedures is the responsibility of diagnostic 
facility to ensure good laboratory practice and is 
integral to provide good patient care.
At Aga Khan University clinical laboratories, 
immunophenotyping by fl ow cytometry is offered 
for the diagnosis of leukaemia, lymphoma, minimal 
residual disease, ZAP-70 expression, lymphocyte 
subsets and CD34 count.
Reference: 
Owens MA, Vall HG, Hurley AA, Wormsley SB. Validation and quality 
control of immunophenotyping in clinical fl ow cytometry. J Immunol 
Methods.  2000 21;243(1-2):33-50.
Validation of Modern Flow Cytometry Instrument 
Dr Muhammad Shariq Shaikh, Dr. Arsalan Ahmed and 
Sarwat Kashif
Haematology and Histopathology
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According to Food and Drug Administration, 
validation is ‘‘Establishing documented evidence 
which provides a high degree of assurance that a 
specifi c process will consistently produce a product 
meeting its predetermined specifi cations and quality 
attributes.” College of American Pathologist (CAP) 
regulations require that performance for any new 
method be ‘‘verifi ed’’ prior to reporting patient’s 
test results. Precision and accuracy are specifi cally 
identifi ed, along with analytical sensitivity, analytical 
specifi city, reportable range, reference values, and 
any other applicable characteristic. The responsibility 
for method verifi cation or validation resides with 
each laboratory and is accountable to see that 
adequate data has been collected and that this data 
shows that the new methods provide acceptable 
performance in the laboratory. Following protocol 
should be followed in validating a new test and it 
should be documented.
Verifi cation of Precision
Precision implies repeatability, which means, 
analyze repeatedly to determine variation. To verify 
precision, samples should be processed twice a 
day in quadruplicate for fi ve days generating 20 
replicates. This is called inter-assay variation. For 
intra-assay variation, one sample was run 20 times. 
Imprecision is quantifi ed by calculating the mean, 
standard deviation (SD), and coeffi cient of variation 
(CV %) of data collected from an analytical run: CV 
= SD/Mean x 100.Precision can be specifi ed as: (i) 
repeatability (within run), (ii) intermediate precision 
(long term) and reproducibility (interlaboratory). If 
the precision is less than the total allowable error for 
that analyte then method is precise.
Verifi cation of Accuracy
Agreement between test result and ‘‘true’’ result is 
done in mainly two ways: 
(i) Comparison of results between new method and  
 ‘‘reference’’ method (Method comparison)  
(ii) Results using new method on certifi ed reference  
 materials or controls (Recovery) 
The fi rst approach is most commonly used. For this 
run 20 samples within testing range (CLSI document 
EP15-A2) by both new and comparative methods, 
and check whether the average bias between the two 
methods is within allowable limits or not. Recovery 
is done when there is no comparative method 
available and it should also be within total allowable 
error for the accuracy to be verifi ed.
Verifi cation of Reportable Range (AMR & CRR)
Reportable range is the span of test result values over 
which the lab can establish or verify the accuracy of 
the measurement response. 
Analytical Measurement Range (AMR)
Range of analyte values that a method can directly 
measure on the specimen, without any dilution, 
or other pretreatment, not part of the usual assay 
process. AMR must be verifi ed before a method is 
introduced, and checked at least every six months 
(and after recalibration or major maintenance) while 
in use.  AMR verifi cation must include three levels—
low, midpoint, high. One can use commercial 
linearity materials, profi ciency testing (PT) samples, 
controls or patient samples with known results, 
standards or calibrators. It can also be done by 
calibration verifi cation, if three samples that span 
the measurement range are used.  In absence of 
commercial materials, one will need to create one’s 
own materials. High and low samples can be mixed 
to create a mid-point sample. If it is found to be 
higher than measurement limit, one can dilute with 
low level sample to create a level near limit. 
Clinically Reportable Range (CRR)
It is the range of analyte values that are reported as 
a quantitative result, allowing for specimen dilution 
or other pretreatment used to extend the actual AMR. 
CRR is a clinical decision by the laboratory director/
section heads, and does not require experiments or 
re-validation; however, dilution or concentration 
protocols must be specifi ed in methods. 
Method Validation for Quantitative Tests: 
CAP Recommendations
Dr Noreen Sherazi
Chemical Pathology
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Verifi cation or Establishment of Reference 
Intervals
It is not required for a laboratory to establish its 
own reference limits, but satisfy that limits it uses 
are appropriate for the patients. According to CLSI 
document C 28-A2, it is very useful to be able to 
transfer a reference interval from one laboratory 
to another by some process of validation which is 
less costly and more convenient. One can adopt 
Barcode is a system of using varying width bars 
as a way to provide identifi cation information. It 
is an optical machine-readable representation of 
data, which shows certain data on certain products.
in laboratory.  Its purpose is to ensure sample 
identifi cation and accession. Bar codes consist of 
a series of small parallel lines of varying width 
that are used to represent numbers or letters and 
numbers and are readable by automated equipment. 
There are many types of barcodes the most common 
ones being one dimensional and two dimensional. 
In single dimensional barcode the vertical lines 
and their spacing constitute the code but whole 
length of the vertical lines are not essential for the 
codes. It is said that the code is repeated in vertical 
directions. So a symbol with printing defects, such 
as spots or voids, can still be read. On the other 
hand, two dimensional barcode stores information 
along the height as well as the length of symbol. 
As a result of that construction, these barcodes 
have a greater storage than is possible with the one 
dimensional barcode. A two dimensional barcode 
is not comprised of bars or lines, but rather of 
black-and-white cells arranged in a matrix pattern 
(often laid out in a square). This square design is 
Barcoding for Reducing Pre-analytical Errors 
in a Clinical Laboratory
Sheharbano Imran
Chemical Pathology
reference limits from any of the following sources: 
manufacturer suggested, reference laboratory, 
published articles, neighboring laboratory or 
previous reference limits in the same laboratory. 
For verifying reference intervals, we should select 
20 representative healthy individuals, and the test 
will considered validated if, ≤ 2 of them is outside 
the manufacturer’s proposed limit. If >2 outside, 
can repeat with another 20, and accept if ≤ 2 is 
outside.
often easier to scan than lineal barcodes because it 
fi ts better on curved surfaces such as test tubes or 
patient wristbands. 
Bar-coding the specimen label greatly 
minimizes clerical errors and decreases errors 
in patient specimen handling as well as increase 
productivity. For clinical laboratories, timely and 
accurate specimen labeling is expected to ensure 
correct patient identifi cation from collection to 
results reporting. Electronic identifi cation such as 
two dimensional barcodes can certainly include 
two or more person-specifi c identifi ers to comply 
with this requirement. Barcodes clearly provide 
patient tracking and sample management. They 
speed up record retrieval and are more secure 
for patients in terms of anonymity, accuracy, 
and elimination of human error. With barcodes, 
transcription errors and hard-to-read labels can be 
removed from the workplace. Besides laboratory 
specimens barcodes can be used on reagents/ kits, 
quality controls, calibrators and blood products in 
a clinical laboratory. With a high quality barcode 
label, a working scanner, and a trained operator, 
data collection can happen at lightening speeds 
with 100 per cent data accuracy. 
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Levey Jenning chart (LJ chart) is a graph on 
which the quality control data is plotted on. It is 
named after S. Levey and E. R. Jennings who in 
1950 suggested the use of Shewhart’s individuals 
control chart in the clinical laboratory. It is a 
visual indication whether a laboratory test is 
working well or not. The data obtained from the 
daily analysis of quality control pools can be 
plotted to create a visual analysis.  The expected 
analyte concentration, the established target 
value (mean), and the desired number of standard 
deviations are drawn on the y-axis, and the days of 
the month are indicated on x-axis. Lines run across 
the graph at the mean, as well as one, two and 
sometimes three standard deviations either side of 
the mean. This makes it easy to see how far off the 
result was. 
Rules, such as the Westgard rules can be applied 
to see whether the results from the samples 
when the control was done can be released, or 
if they need to be rerun. In 1981, Dr. James 
Westgard and his associates developed a multi-
rule procedure for interpreting control data. Since 
then, a number of sophisticated quality control 
schemes or analogues based on this multi-rule 
logic have evolved.  Westgard rules are quality 
control rules to help analyze whether or not an 
analytical run is in-control or out-of-control. Any 
values violating Westgard rules will be either 
rerun or rejected depending on the rule violated. 
It uses a combination of decision criteria, 
usually five different control rules to judge the 
acceptability of an analytical run. Westgard rules 
specify the LJ chart. It makes use of a series of 
control rules for interpreting control data and 
also reduces the false rejection and improves 
the error detection. The formulation of Westgard 
rules were based on statistical methods. They are 
used to define specific performance limits for a 
particular assay and can be used to detect both 
random and systematic errors. For convenience, 
a short hand notation to abbreviate different 
decision criteria or control rules, e.g., 12s to 
indicate one control measurement exceeding 2s 
control limits is used.
Levey Jenning Chart and a Guide to Use 
Westgard Rules
Dr Sheharbano and Dr Lena Jafri
Chemical Pathology
Explanation of Individual Rules and 
Troubleshooting
12s : One control measurement exceeding two 
standard deviations (SD) of control limits either 
above or below the mean. This rule is used a warning 
rule to trigger careful inspection of the control data. 
(Figure 1) False alarms are minimized by using 
the 12s rule as a warning rule, then confi rming any 
problems by application of more specifi c rules that 
have a low probability of false rejection. 
13s : This rule is commonly used with a LJ chart 
when the control limits are set as the mean +3 SD 
of control limits. A run is rejected when a single 
control measurement exceeds the mean ± 3 SD. 
This is because either a random error or a very large 
systematic error has occurred, as less than one per cent 
of all test values exceed ± 3SD. Troubleshooting must 
be performed before further testing can be done.
22s : Westgard rule 22s  states that if two 
consecutive control measurements across runs 
exceed the same mean -2 SD or exceed the same 
mean +2SD, or, within a run, if two consecutive 
control values are outside the same two SD, the 
run must be rejected. If this circumstance occurs, a 
systematic error is likely. Troubleshooting must be 
performed before testing can continue. Had only 
one of the controls been greater than +2SD, the 
run would have been accepted as “in control,” but 
would have been rejected on the next QC run if the 
same control was again out +2SD.
R4s : This rule rejects a run if two control 
measurements in a group exceed the mean with a four 
SD difference between the two consecutive controls.
41s : This rule rejects a run with the forth consecutive 
control measurement exceeding one SD on the same 
side of the mean. 41s is when four consecutive control 
measurements exceed the same  mean plus one SD or 
the same mean minus one SD control limit.
10x : This rule rejects a control run when there are 10 
consecutive controls on the same side of the mean.
16
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True alarms or error detection are maximized 
by selecting a combination of the Westgard 
rules most sensitive to detection of random 
and systematic errors and then rejecting a run 
if any one of these rules is violated (parallel 
testing). The key in how to apply control rules 
with multiple materials and multiple runs is to 
identify which quality control results represent 
consecutive measurements. For example if one 
measurement is made on each of two different 
control materials in an analytical run, control 
rules can be applied as follows: the two control 
results ‘within a run’ can be inspected by applying 
Figure 1: Graphs showing interpretation of Westgard rules on LJ charts (courtesy westgard.com)
a 13s rule to each material, as well as the 22s 
and R4s rules ‘across materials’. Likewise 
the 10x rule can be applied to both control 
measurement in a run for the last five runs, or 
to the measurements on just one material for the 
last ten runs. Westgard rules are programmed 
in to automated analyzers to determine when an 
analytical run should be rejected. These rules 
need to be applied carefully so that true errors 
are detected while false rejections are minimized. 
The rules applied to high volume chemistry and 
hematology instruments should produce low false 
rejection rates.
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Quality Control of VITEK-2 System
Asima S. Sabzwari
Clinical Microbiology
VITEK-2 system is an automated system for 
antimicrobial susceptibility testing. As with any 
automated system, it is very important to maintain 
quality control (QC) as microbial contaminants can 
enter a bio-manufacturing product system and impact 
the product outcome. QC is also performed to check 
that the instrument is functioning properly and all the 
values are within the reference ranges.
Principle
VITEK-2 system use advanced colorimetry, an 
identifi cation technology that enables identifi cation 
of routine clinical isolates. Advanced colorimetry 
provides a low rate of misidentifi ed species and 
susceptibility testing can be performed accurately in 
a shorter period of time. The VITEK-2 Antimicrobial 
Susceptibility Test (AST) card is an automated 
version of determining the minimum inhibitory 
concentration (MIC). Each AST card contains 64 
wells including a control well and wells containing 
premeasured portions of a specifi c antibiotic tested 
against a standardized suspension of bacterial or 
yeast isolates for 7-12 hours. 
At the completion of the incubation cycle, a report 
is generated that contains the MIC value along with 
the interpretive category result for each antibiotic 
contained on the card.
The rapid results allow clinicians to discontinue 
empiric therapy and prescribe targeted therapy, 
resulting in improved patient outcomes and enhanced 
antibiotic stewardship.
Quality Control
The consistency of results as analysed by the Vitek 
expert system indicates that the isolate fi ts an 
expected pattern for a defi ned phenotype. Results can 
be rapidly and confi dently released with little or no 
intervention by laboratory personnel. Daily protocols 
are followed to control environmental factors and to 
maintain sterility for assuring quality through day 
to day operations. Important steps taken to maintain 
quality control of the VITEK-2 System include:
 QC of reference strains being done and the values  
 are compared with standards. The results must 
 be within recommended ranges as per guidelines 
 for susceptibility results to be valid.
 VITEK-2 dispenser is cleaned with distilled water  
 to remove any deposits and autoclaved weekly to  
 maintain sterility.
 The tips used are also autoclaved before preparing  
 suspensions
 The tubes used for making suspensions are   
 sterilized by ethylene oxide
 Sterility check is performed daily to rule out  
  the contamination of the dispenser and 
Vitek saline to ensure that the saline and 
dispenser are not contaminated with any 
foreign particle/bacteria
 For each isolate to be tested, purity  
 plate is setup to ensure that the   
 isolate is pure at the completion of  
 the process. If the purity plates are  
 not pure then the results are not valid  
 and should be repeated. 
Annual service conducted by 
manufacturer and on monthly basis PPM 
(planned preventive maintenance) by the 
vendor.VITEK-2 System
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Profi ciency Testing as a Quality Improvement 
Tool in Clinical Microbiology Laboratories
Dr Kauser Jabeen 
Clinical Microbiology 
Infectious diseases are a great threat globally to 
human health. The morbidity and mortality related 
to infections is aggravated further in settings with 
limited resources, lack of government commitment 
and poor infrastructure. Clinical microbiology 
laboratories are pivotal for the diagnosis of 
infection and detection of antimicrobial resistance. 
It is therefore extremely critical that laboratories 
should ensure generation of accurate and precise 
results. In order to produce quality assured 
results it is essential that laboratories should have 
quality management systems in place. Profi ciency 
testing (PT) is an external quality assessment 
tool that is used to assess laboratory performance 
and quality of results.  It is recommended that 
clinical laboratories should participate in the PT 
programs. Alternate assessment of a split sample 
approach should be followed for a test for which 
an approved PT program is not available. The 
laboratory could also perform blinded testing 
of simulated specimens or use photographs or 
photomicrographs for this purpose.
The components and requirement of PT include 
enrollment in approved PT program, regular 
participation, meet criteria set by the PT 
program. It is essentially important that the PT 
samples are processed using similar protocols 
and methodology as a regular patient specimen 
is tested. Repeat testing should be avoided and 
all technologists involved in reporting should be 
provided with an equal opportunity to process 
and report PT sample. The PT result should be 
reported within the recommended time frame. 
After receiving the result the results should be 
compared with inter-laboratory comparison. In 
case of an incorrect result, the process should be 
reviewed to identify the cause of error. Corrective 
actions should be taken and ongoing monitoring 
continued. 
Participation in a PT program could also be 
helpful as it could be used as a bench mark quality 
indicator of a laboratory. It could also be used as a 
marketing tool to instill confi dence in the customer 
that this laboratory produces quality results. It 
could be used a toll to assess staff’s competency 
and as an education tool for teaching and training 
of staff and junior doctors. 
In conclusion regular participation in PT testing 
program is essential for a clinical laboratory as it 
is a valuable quality improvement tool. In Pakistan 
this participation is not a regulatory requirement, 
however many quality assured laboratories, such 
as the Aga Khan University laboratory regularly 
participate in the College of American Pathologists 
PT program. 
Reference: 
Stang LH, Anderson NL. Use of profi ciency testing as a tool to improve 
quality in microbiology laboratories. Clin Microbiol Newletter 2013; 35: 
145-52.
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Establishing Quality Control Values for 
Haematology Parameters
Dr Muhammad Shariq Shaikh
Haematology
Quality control (QC) in the medical laboratory is 
a statistical process used to monitor and evaluate 
the analytical process that produces patient results. 
A quality control product is a patient-like material 
ideally made from human body fl uids and contains 
one or more analyte in known concentration. In 
order to assess the validity of results on patient 
specimens, use of QC material is a requirement 
put forth by regulatory agencies. It is essential 
for laboratories to fulfi ll or surpass the regulatory 
standards set by regulatory agencies.
For most haematology analyzers, the target QC 
value and its limits for each analyte are provided by 
the vendor. These values are calculated by repeated 
testing of QC material and are provided in an assay 
sheet with each new lot of controls. However, 
owing to variation in different laboratories, 
instrument calibration, maintenance, reagents and 
operator technique, these values may not be the 
exact target value in a given laboratory. 
Both The Joint Commission on Accreditation 
of Health Care Facilities (JCAHO) and College 
of American Pathologists (CAP) recommend 
calculation of own target values by each laboratory. 
This approach may not be a cost-effective option 
for the laboratories catering small number of patient 
samples. Utilization of manufacturer provided 
QC values however, is permitted as a guide for 
establishing own QC values and for very low 
volume tests where the range is narrow enough to 
detect clinically signifi cant errors.
Calculation of own target values is a rather 
easy task. The new control should be analyzed 
a minimum of 20 times across three to five 
days. The average of these 20 values should be 
within the range stated on manufacturer provided   
assay sheet. A two standard deviation range 
should be calculated from this new target value 
for setting up the upper and lower limits. These 
new values should then be incorporated into the 
system and utilized throughout the dating of the 
product.
Mean corpuscular volume (MCV) is a 
haematology parameter that requires special 
consideration. It has tendency to rise by two 
units over the life of the control material. To 
accommodate this, it is acceptable to raise the new 
calculated target value by half this change (by one 
unit). This will result in values starting below the 
mean, rise through the mean and fi nish above the 
mean.
One drawback of establishing own QC values is 
an increased utilization of expensive commercial 
controls. However, in view of recommendations of 
regulatory bodies, each laboratory should establish 
its own quality control values to ensure reliability 
of test results thus avoiding medically signifi cant 
errors.
References: 
The Joint Commission - www.jointcommission.org
College of American Pathologists - www.cap.org 
hospitals.aku.edu/Karachi/clinical-laboratories
